OncLive TV

Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Alec Watson, MD, discusses clinically relevant thresholds for HER2, KRAS, and MET gene copy number gain set by oncogene overlap analysis in NSCLC.

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER-positive, HER2-negative breast cancer.

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

John Mascarenhas, MD, discusses preclinical and clinical data showing symptom improvement and spleen responses with navtemadlin in myelofibrosis.

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.

Maximilian Stahl, MD, discusses considerations for genetic testing to determine if patients with acute myeloid leukemia may be candidates for a menin inhibitor.

Abhirami Vivekanandarajah, MD, shares how she tests and treats patients with HER2-mutated non–small cell lung cancer in the community setting.

Balazs Halmos, MD, discusses novel targets for drug development in small cell lung cancer.

Balazs Halmos, MD, discusses challenges associated with the diagnosis and treatment of patients with small cell lung cancer.

Ghayas C. Issa, MD, discusses the efficacy of revumenib in relapsed or refractory KMT2A-rearranged leukemias.

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

Tracy I. George, MD, discusses and how ultra-sensitive duplex sequencing may address key limitations of current diagnostic tools for indolent systemic mastocytosis.

Elias Jabbour, MD, discusses frontline treatment considerations in newly diagnosed acute lymphocytic leukemia.

Bently P. Doonan, MD, discusses treatment strategies for patients with advanced melanoma who have progressed on checkpoint inhibitors.

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.